Global Information
회사소개 | 문의 | 위시리스트

간경변 치료제 시장 : 기회 평가, 역학 예측, 시장 역학, 파이프라인 분석, 현재 시장 규모, 시장 예측

Liver Cirrhosis Therapeutic Market (Opportunities Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analysis, Current Market Size and Market Forecast 2018 - 2028)

리서치사 GervanoRA Data Services LLP
발행일 2019년 02월 상품 코드 769587
페이지 정보 영문 207 Pages
가격
US $ 3,500 ₩ 4,251,000 PDF by E-mail (General License)


간경변 치료제 시장 : 기회 평가, 역학 예측, 시장 역학, 파이프라인 분석, 현재 시장 규모, 시장 예측 Liver Cirrhosis Therapeutic Market (Opportunities Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analysis, Current Market Size and Market Forecast 2018 - 2028)
발행일 : 2019년 02월 페이지 정보 : 영문 207 Pages

세계의 간경변 치료제(Liver Cirrhosis Therapeutic) 시장에 대해 조사했으며, 역학 예측, 시장 역학, 파이프라인 치료제 승인 스케줄 예측, 임상시험 요약, 현재·향후 경쟁 상황, 주요 기업 개요, 신흥 기업 개요, 파이프라인 치료제의 설명과 개발 마일스톤 등에 대해 분석했습니다.

제1장 서론

제2장 주요 요약

제3장 질환 개요

  • 질환 정의와 증상
  • 병인과 분류
  • 질환 진단
  • 치료 알고리즘과 가이드라인
  • 역학과 질병 부담
  • 역학 예측

제4장 시장 개요

  • 정부 규제 역학과 영향
  • 가격과 의료비 상환
  • 계약
  • 신약 승인(US FDA)
  • 신약 승인(EMA)
  • 특허 분석(만료와 제네릭 의약품)

제5장 파이프라인 분석과 승인 스케줄 예측

  • 파이프라인 분석 : 개발 단계별
  • 파이프라인 분석 : 지역별
  • 파이프라인 분석 : 투여 경로별
  • 파이프라인 분석 : 약제 클래스별
  • 파이프라인 분석 : 작용기서별
  • 파이프라인 분석 : 적응증별
  • 파이프라인 분자 분석 : 대학 및 기관별
  • 승인 스케줄 예측

제6장 간경변 임상시험 요약

  • 간경변 파이프라인 분석 : 임상시험 결과별
  • 지속중인 임상시험 요약
  • 계획중인 임상시험 요약
  • 최근 완료된 임상시험 요약

제7장 간경변 시장 : 약제 클래스별

제8장 간경변 시장 : 투여 경로별

제9장 간경변 시장 : 지역별

  • 미국
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 일본
  • 중국
  • 인도
  • 브라질
  • 러시아
  • 기타(RoW)

제10장 현재 및 향후 경쟁 상황

  • 기업
  • 대학 및 기관

제11장 약어

KSM 19.01.18

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

GervanoRA's Market Estimation report "Liver Cirrhosis: Opportunity Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analysis, Current Market Size and Market Forecast (2018-2028)" analyzed the current and upcoming opportunities in the Liver Cirrhosis area by assessing the drug market, covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Liver Cirrhosis industry. The report has been divided into segments like Disease Overview, Market Overview, Pipeline Analysis and Clinical Trials summary to provide in depth insights about the market dynamics and ongoing R&D in the Liver Cirrhosis area. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Molecules by Geography, Pipeline Molecules by Drug Class, Pipeline Molecules by Mechanism of Action and Pipeline Molecules by Stage of development. The report evaluated the current market scenario by estimating the market value with respect to Liver Cirrhosis Drug Class, Route of Administration and Distribution Channel. Report primarily focuses on the patent analysis of the key pipeline drugs to provide a brief understanding about the market opportunities in the Liver Cirrhosis competitive environment. We have also prognosticated the Liver Cirrhosis market share in 11 Major Markets to aid our clients with the commercial and economic opportunities in these geographies. Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on * Epidemiology and Epidemiology forecast 2018-2023 * Market Dynamics with Coverage of Deals (Mergers, Acquisitions, Partnering, Collaborations etc.) * Estimated Pipeline Drug Approval Timelines * Clinical Trials Summary * Current and Future Competitive Landscape * Key Company Profiles with SWOT Analysis * Emerging Company Profiles with Opportunity Assessments * Pipeline Drug Descriptions along with Development milestones (Past and Future)

TABLE OF CONTENTS 1 INTRODUCTION

  • 1.1. REPORT DESCRIPTION
  • 1.2. METHODOLOGY
  • 1.3. UPCOMING AND OTHER AVAILABLE PIPELINE ANALYSIS REPORTS
  • 1.4. ABOUT US: GERVANORA DATA SERVICES

2 EXECUTIVE SUMMARY

  • 2.1. MARKET SNAPSHOT, 2018-2028
  • 2.2. KEY PIPELINE EVENTS (REGULATORY APPROVALS) 2020-2035
  • 2.3. KEY MAJOR FINDINGS
    • 2.3.1. DRIVERS
    • 2.3.2. RESTRAINTS
    • 2.3.3. OPPORTUNITIES

3 DISEASE OVERVIEW

  • 3.1. DISEASE DEFINITION & SYMPTOMS
  • 3.2. DISEASE CAUSE AND CLASSIFICATION
  • 3.3. DISEASE DIAGNOSIS
  • 3.4. TREATMENT ALGORITHM AND GUIDELINES
  • 3.5. EPIDEMIOLOGY AND DISEASE BURDEN
  • 3.6. EPIDEMIOLOGY FORECAST
    • 3.6.1. FORECAST METHODOLOGY AND ASSUMPTION
    • 3.6.2. PROBABILISTIC EPIDEMIOLOGY FORECAST

4 MARKET DYNAMICS

  • 4.1. DEALS (MERGERS/ ACQUISITIONS / COLLABORATIONS)

5 PIPELINE ANALYSIS AND ESTIMATED APPROVAL TIMELINE

  • 5.1. PIPELINE ANALYSIS BY STAGE OF DEVELOPMENT
    • 5.1.1. PHASE 3 MOLECULES
    • 5.1.2. PHASE 2 MOLECULES
    • 5.1.3. PHASE 1 MOLECULES
    • 5.1.4. PRECLINICAL MOLECULES
    • 5.1.5. EARLY R&D MOLECULES
  • 5.2. PIPELINE ANALYSIS BY INDICATION
  • 5.3. PIPELINE ANALYSIS BY GEOGRAPHY
    • 5.3.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.4. PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION
    • 5.4.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.5. PIPELINE ANALYSIS BY DRUG CLASS
    • 5.5.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.6. PIPELINE ANALYSIS BY MECHANISM OF ACTION
    • 5.6.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.7. ESTIMATED APPROVAL TIMELINES
    • 5.7.1. METHODOLOGY
    • 5.7.2. ESTIMATED APPROVAL TIMELINES US & EX-US

6 LIVER CIRRHOSIS CLINICAL TRIALS SUMMARY

  • 6.1. LIVER CIRRHOSIS PIPELINE ANALYSIS BY CLINICAL TRIALS RESULTS
    • 6.1.1. KEY PHASE 3 CLINICAL TRIAL RESULTS
    • 6.1.2. KEY PHASE 2 CLINICAL TRIAL RESULTS
  • 6.2. ONGOING CLINICAL TRIALS SUMMARY

7 GLOBAL LIVER DISEASES MARKET BY DRUG CLASS

  • 7.1. DIURETICS
  • 7.2. ANTIVIRAL DRUGS
  • 7.3. BETA-BLOCKERS (Β-BLOCKERS)
  • 7.4. HORMONES
  • 7.5. ANTIBIOTICS
  • 7.6. AMMONIA REDUCER

8 LIVER CIRRHOSIS MARKET, BY ROUTE OF ADMINISTRATION

  • 8.1. ORAL
  • 8.2. INJECTABLES

9 LIVER CIRRHOSIS MARKET, BY DISTRIBUTION CHANNEL

  • 9.1. HOSPITAL PHARMACIES
  • 9.2. RETAIL PHARMACIES
  • 9.3. ONLINE PHARMACIES

10 GLOBAL LIVER CIRRHOSIS THERAPEUTIC MARKET BY GEOGRAPHY

  • 9.1 US
  • 9.2 UK
  • 9.3 GERMANY
  • 9.4 FRANCE
  • 9.5 ITALY
  • 9.6 SPAIN
  • 9.7 JAPAN
  • 9.8 CHINA
  • 9.9 INDIA
  • 9.1 BRAZIL
  • 9.11 RUSSIA
  • 9.12 ROW

11 CURRENT AND FUTURE COMPETITIVE LANDSCAPE

  • 11.1. ESTABLISHED COMPANIES
    • 11.1.1. ESTABLISHED COMPANIES AND SWOT
  • 11.2. EMERGING COMPANIES
    • 11.2.1. EMERGING COMPANY PROFILES WITH DRUG DESCRIPTIONS

12 ABBREVIATIONS

LIST OF TABLES

  • TABLE 01: REPORT HIGHLIGHTS IN NUMERICALS
  • TABLE 02: LIVER CIRRHOSIS EPIDEMIOLOGY (2017), FORECAST (2018-2023), US AND EU
  • TABLE 03: MAJOR ACQUISITIONS AND MERGERS IN LIVER DISEASES THERAPEUTIC AREA
  • TABLE 04: MAJOR COLLABORATIVE AGREEMENTS IN LIVER DISEASES THERAPEUTIC AREA
  • TABLE 05: MAJOR LICENSING AGREEMENTS IN LIVER DISEASES THERAPEUTIC AREA
  • TABLE 06: MAJOR PARTNERSHIPS IN LIVER DISEASES THERAPEUTIC AREA
  • TABLE 07: PHASE 3 MOLECULES IN THE LIVER DRUG PIPELINE
  • TABLE 08: PHASE 2 MOLECULES IN THE LIVER DISEASES DRUG PIPELINE
  • TABLE 09: PHASE 1 MOLECULES IN THE LIVER DRUG PIPELINE
  • TABLE 10: PRECLINICAL MOLECULES IN THE LIVER DISEASE DRUG PIPELINE
  • TABLE 11: EARLY R&D MOLECULES IN THE LIVER DISEASE DRUG PIPELINE
  • TABLE 12: LIVER CIRRHOSIS PIPELINE MOLECULES, BY INDICATION TYPE
  • TABLE 13: LIVER DISEASES DRUG PIPELINE MOLECULES BY ORAL AS ROUTE OF ADMINISTRATION
  • TABLE 14: LIVER DISEASES DRUG PIPELINE MOLECULES BY INTRAVENOUS AS ROUTE OF ADMINISTRATION
  • TABLE 15: LIVER DISEASES DRUG PIPELINE MOLECULES BY INJECTABLE AS ROUTE OF ADMINISTRATION
  • TABLE 16: LIVER DISEASES DRUG PIPELINE MOLECULES BELONGING TO FXR DRUG CLASS
  • TABLE 17: LIVER DISEASES DRUG PIPELINE MOLECULES BELONGING TO TLR INHIBITORS DRUG CLASS
  • TABLE 18: ESTIMATED APPROVAL TIMELINES OF PIPELINE MOLECULES
  • TABLE 19: LIVER CIRRHOSIS PIPELINE DRUGS CLINICAL TRIALS SUMMARY
  • TABLE 20: CENICRIVIROC (CVC) AURORA STUDY DESIGN
  • TABLE 21: SELADELPAR ENHANCE STUDY DESIGN
  • TABLE 22: ELAFIBRANOR RESOLVE-IT STUDY DESIGN
  • TABLE 23: OCA REGENERATE STUDY DESIGN
  • TABLE 24: OCA REVERSE STUDY DESIGN
  • TABLE 25: ARAMCHOL ARREST STUDY DESIGN
  • TABLE 26: MGL-3196 PHASE 2 STUDY DESIGN
  • TABLE 27: GLOBAL LIVER CIRRHOSIS MARKET BY DRUG CLASS, MARKET SIZE (2017) AND FORECAST (2018-2028)
  • TABLE 28: GLOBAL DIURETICS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 29: GLOBAL DIURETICS MARKET FOR LIVER CIRRHOSIS BY COUNTRY, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 30: GLOBAL ANTIVIRAL DRUGS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 31: GLOBAL ANTIVIRAL DRUGS MARKET FOR LIVER CIRRHOSIS BY COUNTRY, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 32: GLOBAL BETA-BLOCKERS MARKET FOR LIVER CIRRHOSIS BY COUNTRY, MARKET SIZE (2017) AND FORECAST (2018-2028)
  • TABLE 33: GLOBAL HORMONES MARKET FOR LIVER CIRRHOSIS BY COUNTRY, MARKET SIZE (2017) AND FORECAST (2018-2028)
  • TABLE 34: GLOBAL ANTIBIOTICS MARKET FOR LIVER CIRRHOSIS BY COUNTRY, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 35: GLOBAL AMMONIA REDUCER MARKET FOR LIVER CIRRHOSIS BY COUNTRY, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 36: GLOBAL LIVER CIRRHOSIS MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 37: GLOBAL LIVER CIRRHOSIS MARKET FOR ORAL DRUGS BY COUNTRY, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 38: GLOBAL LIVER CIRRHOSIS MARKET FOR INJECTABLE DRUGS BY COUNTRY, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 39: GLOBAL LIVER CIRRHOSIS MARKET FOR DISTRIBUTION CHANNEL TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 40: GLOBAL LIVER CIRRHOSIS MARKET FOR HOSPITAL PHARMACIES BY COUNTRY, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 41: GLOBAL LIVER CIRRHOSIS MARKET FOR RETAIL PHARMACIES BY COUNTRY, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 42: GLOBAL LIVER CIRRHOSIS MARKET FOR ONLINE PHARMACIES BY COUNTRY, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 43: GLOBAL LIVER CIRRHOSIS MARKET BY COUNTRY, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 44: US LIVER CIRRHOSIS MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 45: US DIURETICS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
  • TABLE 46: US ANTIVIRAL DRUGS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 47: US LIVER CIRRHOSIS MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 48: US LIVER CIRRHOSIS MARKET FOR DISTRIBUTION CHANNEL BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 49: UK LIVER CIRRHOSIS MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 50: UK DIURETICS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 51: UK ANTIVIRAL DRUGS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 52: UK LIVER CIRRHOSIS MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 53: UK LIVER CIRRHOSIS MARKET FOR DISTRIBUTION CHANNEL BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
  • TABLE 54: GERMANY LIVER CIRRHOSIS MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
  • TABLE 55: GERMANY DIURETICS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 56: GERMANY ANTIVIRAL DRUGS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
  • TABLE 57: GERMANY LIVER CIRRHOSIS MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 58: GERMANY LIVER CIRRHOSIS MARKET FOR DISTRIBUTION CHANNEL BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 59: FRANCE LIVER CIRRHOSIS MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 60: FRANCE DIURETICS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 61: FRANCE ANTIVIRAL DRUGS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 62: FRANCE LIVER CIRRHOSIS MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 63: FRANCE LIVER CIRRHOSIS MARKET FOR DISTRIBUTION CHANNEL BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 64: ITALY LIVER CIRRHOSIS MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 65: ITALY DIURETICS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 66: ITALY ANTIVIRAL DRUGS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 67: ITALY LIVER CIRRHOSIS MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 68: ITALY LIVER CIRRHOSIS MARKET FOR DISTRIBUTION CHANNEL BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 69: SPAIN LIVER CIRRHOSIS MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 70: SPAIN DIURETICS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 71: SPAIN ANTIVIRAL DRUGS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 72: SPAIN LIVER CIRRHOSIS MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 73: SPAIN LIVER CIRRHOSIS MARKET FOR DISTRIBUTION CHANNEL BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 74: JAPAN LIVER CIRRHOSIS MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 75: JAPAN DIURETICS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
  • TABLE 76: JAPAN ANTIVIRAL DRUGS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 77: JAPAN LIVER CIRRHOSIS MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 78: JAPAN LIVER CIRRHOSIS MARKET FOR DISTRIBUTION CHANNEL BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 79: CHINA LIVER CIRRHOSIS MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
  • TABLE 80: CHINA DIURETICS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
  • TABLE 81: CHINA ANTIVIRAL DRUGS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
  • TABLE 82: CHINA LIVER CIRRHOSIS MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 83: CHINA LIVER CIRRHOSIS MARKET FOR DISTRIBUTION CHANNEL BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 84: INDIA LIVER CIRRHOSIS MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 85: INDIA DIURETICS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 86: INDIA ANTIVIRAL DRUGS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 87: INDIA LIVER CIRRHOSIS MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 88: INDIA LIVER CIRRHOSIS MARKET FOR DISTRIBUTION CHANNEL BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 89: BRAZIL LIVER CIRRHOSIS MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 90: BRAZIL DIURETICS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 91: BRAZIL ANTIVIRAL DRUGS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 92: BRAZIL LIVER CIRRHOSIS MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 93: BRAZIL LIVER CIRRHOSIS MARKET FOR DISTRIBUTION CHANNEL BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 94: RUSSIA LIVER CIRRHOSIS MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 95: RUSSIA DIURETICS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 96: RUSSIA ANTIVIRAL DRUGS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 97: RUSSIA LIVER CIRRHOSIS MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 98: RUSSIA LIVER CIRRHOSIS MARKET FOR DISTRIBUTION CHANNEL BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 99: ROW LIVER CIRRHOSIS MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 100: ROW DIURETICS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 101: ROW ANTIVIRAL DRUGS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 102: ROW LIVER CIRRHOSIS MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 103: ROW LIVER CIRRHOSIS MARKET FOR DISTRIBUTION CHANNEL BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
  • TABLE 104: MAJOR PRODUCTS: MERCK
  • TABLE 105: MERCK'S NEW MOLECULAR ENTITIES UNDER REVIEW
  • TABLE 106: MERCK'S PHASE 3 DRUG CANDIDATES
  • TABLE 107: MERCK'S PHASE 2 DRUG CANDIDATES
  • TABLE 108: APPROVALS AND LAUNCHES BY MERCK
  • TABLE 109: R&D ACTIVITIES OF MERCK
  • TABLE 110: CONFERENCES/EVENTS ATTENDED BY MERCK
  • TABLE 111: RECENT DEVELOPMENTS MADE BY MERCK
  • TABLE 112: MAJOR PRODUCTS: GSK
  • TABLE 113: GSK'S KEY PIPELINE DRUG CANDIDATES
  • TABLE 114: APPROVALS AND LAUNCHES BY GSK
  • TABLE 115: R&D ACTIVITIES OF GSK
  • TABLE 116: CONFERENCES/EVENTS ATTENDED BY GSK
  • TABLE 117: RECENT DEVELOPMENTS MADE BY GSK
  • TABLE 118: EMERGING OPPORTUNITIES IN LIVER DISEASES THERAPEUTIC AREA
  • TABLE 119: TERNS PHARMACEUTICALS PIPELINE MOLECULES
  • TABLE 120: R&D MILESTONES ACHIEVED, TERNS PHARMACEUTICALS
  • TABLE 121: PIPELINE PRODUCTS OF CAN-FITE BIOPHARMA
  • TABLE 122: R&D ACTIVITIES OF CAN-FITE BIOPHARMA
  • TABLE 123: PRESENTATIONS/CONFERENCES/EVENTS BY CAN-FITE BIOPHARMA
  • TABLE 124: PUBLICATIONS OF CAN-FITE BIOPHARMA
  • TABLE 125: PARTNERSHIPS BY CAN-FITE BIOPHARMA
  • TABLE 126: RECENT DEVELOPMENTS OF CAN-FITE BIOPHARMA
  • TABLE 127: PIPELINE PRODUCTS OF EA PHARMA
  • TABLE 128: PATENTS OF EA PHARMA
  • TABLE 129: R&D ACTIVITIES OF EA PHARMA
  • TABLE 130: PRESENTATIONS AND PUBLICATIONS BY EA PHARMA
  • TABLE 131: MILESTONES ACHIEVED BY EA PHARMA
  • TABLE 132: RECENT DEVELOPMENTS OF EA PHARMA
  • TABLE 133: PIPELINE PRODUCTS OF CAN-FITE BIOPHARMA
  • TABLE 134: R&D ACTIVITIES OF BIOVIE
  • TABLE 135: RECENT DEVELOPMENTS OF BIOVIE
  • TABLE 136: RECENT ACTIVITIES OF CIRIUS THERAPEUTICS
  • TABLE 137: PUBLICATIONS ON LIVER BY CIRIUS THERAPEUTICS
  • TABLE 138: PIPELINE PRODUCTS OF GENFIT
  • TABLE 139: U.S PATENTS OF GENFIT
  • TABLE 140: R&D ACTIVITIES OF GENFIT
  • TABLE 141: PRESENTATIONS/CONFERENCES/EVENTS ATTENDED BY GENFIT
  • TABLE 142: PUBLICATIONS OF GENFIT
  • TABLE 143: PIPELINE PRODUCTS OF CYMABAY THERAPEUTICS
  • TABLE 144: U.S PATENTS OF CYMABAY THERAPEUTICS
  • TABLE 145: R&D ACTIVITIES OF CYMABAY THERAPEUTICS
  • TABLE 146: ANTICIPATED MILESTONES OF CYMABAY THERAPEUTICS
  • TABLE 147: RECENT DEVELOPMENTS BY CYMABAY THERAPEUTICS
  • TABLE 148: PRESENTATIONS/CONFERENCES/EVENTS BY CYMABAY THERAPEUTICS
  • TABLE 149: R&D ACTIVITIES OF GALMED PHARMACEUTICALS LTD
  • TABLE 150: PRESENTATIONS/CONFERENCES/EVENTS OF GALMED PHARMACEUTICALS LTD
  • TABLE 151: PUBLICATIONS BY GALMED PHARMACEUTICALS LTD
  • TABLE 152: RECENT DEVELOPMENTS OF GALMED PHARMACEUTICALS LTD
  • TABLE 153: PIPELINE PRODUCTS OF ENYO PHARMA SA
  • TABLE 154: R&D ACTIVITIES OF ENYO PHARMA SA
  • TABLE 155: PRESENTATIONS/CONFERENCES/EVENTS BY ENYO PHARMA SA
  • TABLE 156: RECENT DEVELOPMENTS OF ENYO PHARMA SA
  • TABLE 157: PIPELINE PRODUCTS OF POXEL SA
  • TABLE 158: ANTICIPATED MILESTONES OF POXEL SA
  • TABLE 159: R&D ACTIVITIES OF POXEL SA
  • TABLE 160: PRESENTATIONS/CONFERENCES/EVENTS ATTENDED BY POXEL SA
  • TABLE 161: POSTER PRESENTATIONS BY POXEL SA
  • TABLE 162: RECENT DEVELOPMENTS OF POXEL SA

LIST OF FIGURES

  • FIGURE 1: GLOBAL LIVER CIRRHOSIS MARKET 2017-2028: MARKET SNAPSHOT
  • FIGURE 2: GLOBAL LIVER CIRRHOSIS MARKET BY GEOGRAPHY 2017 V/S 2028
  • FIGURE 3: LIVER CIRRHOSIS MARKET BY ROA, 2017
  • FIGURE 4: LIVER CIRRHOSIS MARKET BY DISTRIBUTION CHANNEL, 2017
  • FIGURE 5: KEY PIPELINE EVENTS, 2020-2035
  • FIGURE 6: CIRRHOSIS OF THE LIVER
  • FIGURE 7: PATHOGENESIS AND PATHOPHYSIOLOGY OF CIRRHOSIS OF THE LIVER
  • FIGURE 8: ETILOGY AND COMPLICATIONS OF CIRRHOSIS OF THE LIVER
  • FIGURE 9: CLASSIFICATION OF CIRRHOSIS OF THE LIVER
  • FIGURE 10: LIVER CIRRHOSIS EPIDEMIOLOGY (2017), FORECAST (2018-2023), US AND EU
  • FIGURE 11: OVERALL DEALS ACTIVITY IN LIVER DISEASES THERAPEUTIC AREA
  • FIGURE 12: GEOGRAPHY WISE BREAK UP V/S DEAL TYPE
  • FIGURE 13: DRUG PIPELINE ANALYSIS BY STAGES OF DEVELOPMENT
  • FIGURE 14: LIVER CIRRHOSIS PIPELINE SPLIT BY INDICATION TYPE
  • FIGURE 15: DRUG PIPELINE ANALYSIS BY GEOGRAPHY
  • FIGURE 16: LIVER DISEASE DRUG PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION
  • FIGURE 17: DRUG CLASS CLASSIFICATION OF LIVER DISEASES DRUG PIPELINE
  • FIGURE 18: ONGOING CLINICAL TRIAL SUMMARY
  • FIGURE 19: ANTIVIRAL DRUGS HOLD MAXIMUM SHARE IN THE LIVER CIRRHOSIS MARKET, 2018
  • FIGURE 20: ORAL ROUTE OF ADMINISTRATION IS EXPECTED TO HOLD MAXIMUM SHARE IN THE LIVER CIRRHOSIS MARKET, 2018
  • FIGURE 21: RETAIL PHARMACIES ARE EXPECTED TO HOLD MAXIMUM SHARE IN THE LIVER CIRRHOSIS MARKET, 2018
  • FIGURE 22: US IS EXPECTED TO HOLD MAXIMUM SHARE IN THE LIVER CIRRHOSIS MARKET, 2018
  • FIGURE 23: FINANCIAL INFORMATION OF MERCK, 2018
  • FIGURE 24: SWOT ANALYSIS OF MERCK
  • FIGURE 25: FINANCIAL INFORMATION, GSK
  • FIGURE 26: SWOT ANALYSIS OF GSK
Back to Top
전화 문의
F A Q